About MIRA Pharmaceuticals
MIRA Pharmaceuticals (NASDAQ:MIRA) is a dynamic player in the biotechnology sector, focused on developing innovative treatments to address unmet medical needs. The company's operations span from early-stage research to clinical trials, with projects targeting a variety of diseases. MIRA Pharmaceuticals aims to revolutionize patient care through groundbreaking therapies, leveraging the latest scientific discoveries and a highly skilled team. Their portfolio includes potential treatments for rare diseases, chronic conditions, and life-threatening illnesses, underscoring their commitment to improving health outcomes worldwide. With a forward-thinking approach, MIRA Pharmaceuticals strives to lead the way in biopharmaceutical advancements, ensuring better and more accessible treatments for patients around the globe.
Snapshot
Operations
Products and/or services of MIRA Pharmaceuticals
- Development of innovative oncology drugs targeting resistant cancer cells.
- Research on personalized medicine approaches for effective cancer treatments.
- Advanced diagnostic tools for early detection of various cancers.
- Collaboration on biotechnological advancements in gene therapy.
- Manufacturing high-quality, affordable generic medications for widespread health issues.
- Provision of specialized consulting services to healthcare providers on drug management and patient care.
MIRA Pharmaceuticals executive team
- Mr. Erez AminovCEO & Chairman
- Mr. Alan Weichselbaum CPA, M.B.A.Chief Financial Officer
- Dr. Itzchak Angel Ph.D.Chief Scientific Advisor